Advancing Autoinjector Innovation from Vision to Industry Impact

The development of autoinjectors represents one of the most challenging and impactful areas in drug delivery systems. These devices must seamlessly integrate precision engineering, human-centered design, and strict regulatory requirements, while ensuring safe, reliable, and intuitive use by patients, often in high-stress or physically limiting conditions.

Founded in 2003, DALIMED was built on a foundation of pioneering ideas and patented autoinjectors development. From the very beginning, the company focused on solving some of the most critical challenges in self-injection – combining mechanical innovation with deep understanding of patient needs.

An early commercial partnership with Elcam Medical marked a significant milestone in DALIMED’s journey.

Within this collaboration, DALIMED developed a wide range of mechanical autoinjectors, supporting both disposable and semi-reusable platforms. These solutions were designed to accommodate various primary drug containers, including prefilled syringes, vials, etc.’, addressing the growing diversity of biologic therapies and delivery requirements.

Eventually, Elcam established of a dedicated division – E3D focused specifically on advanced drug delivery devices.

A major turning point came when DALIMED’s developed a 3-Step Autoinjector that was eventually selected by a top10 global pharma company for use with one of the world’s leading blockbuster drugs at the time.

This decision was driven by clear technological advantages over competing solutions. One of the most critical differentiators was DALIMED’s innovative mechanism for shock absorption – significantly reducing mechanical stress/impact on the glass syringe during activation, thereby improving safety, reliability and user experience.

Beyond core performance, the device underwent extensive customization to meet the pharmaceutical company’s specific requirements. Particular attention was given to usability and shape, as many patients using that drug suffer from rheumatoid arthritis – often experiencing reduced hand strength and finger deformities. The result was a highly ergonomic design, tailored to enable safe and comfortable self-administration even under physical limitations.

DALIMED’s involvement extended far beyond concept development. The company led comprehensive Design for Manufacturing (DFM) processes, ensuring that the product’s design is optimized and could be efficiently and consistently produced at scale.

In parallel, DALIMED supported the establishment of a dedicated production line (molds and assembly equipment) at a leading contract manufacturer in the U.S., providing hands-on engineering guidance throughout the transition from development to full-scale manufacturing.

The 3-Step Autoinjector was successfully launched in 2018, marking a significant achievement.

Building on this success, the same platform was relaunched in 2021, featuring a redesigned external appearance, for use with another leading novel biologic. This demonstrated not only the robustness of the original platform, but also its adaptability to evolving branding, user, and therapeutic needs.

Autoinjector development is inherently complex, requiring the alignment of mechanical precision, patient-centric design, regulatory compliance, and scalable manufacturing. DALIMED’s journey in this field highlights its ability to navigate this complexity – transforming innovative concepts into commercially successful products.

Through strategic partnerships, engineering excellence, and a deep commitment to user needs, DALIMED continues to play a key role in shaping the future of self-injection technologies.

DALIMED, in collaboration with E3D, has developed a range of advanced mechanical auto-injector platforms for self-administration, designed to address diverse drug, patient, and market needs. These developments include both disposable and reusable auto-injectors, based on a variety of drug containers, including prefilled syringes (PFS) and vials. Some of the products were designed for chronic therapies requiring frequent injections, while others target emergency-use applications or complex biologic drugs.

The auto-injector platforms developed by DALIMED – including products that were commercially launched and received FDA 510(k) clearance – incorporate a variety of advanced features and capabilities, including – wide range of injection volumes and drug viscosities, passive safety systems with hidden needles before, during, and after injection, quiet operation to reduce patient anxiety and perceived pain, etc.’

These developments highlight DALIMED’s capabilities in inventing, developing, industrializing, and supporting the commercialization of complex drug delivery systems, while addressing the regulatory, clinical, and commercial needs of the global pharmaceutical market.